Posts

FDA 505(b)(2) Breakthroughs: Sun Pharma Depot, Baxter RTU, and Landmark Norwich v. Kennedy Exclusivity Ruling

Image
Summary of the blog post: 2-minute read.  API & IP Intelligence Roundup (07 September 2026) The latest regulatory intelligence highlights vital lifecycle formulation innovations via the USFDA 505(b)(2) pathway, strategic corporate realignments, and a precedential D.C. Circuit ruling overturning FDA's interpretation of 180-day generic exclusivity forfeiture . 1. Recent 505(b)(2) NDA Approvals & Filings (August 2026) The 505(b)(2) pathway continues to deliver differentiated clinical value, de-risking development by building on established reference molecules : Baxter Healthcare (Sodium Bicarbonate Injection, USP — NDA 218524): Approved in ready-to-administer (RTA) Viaflo plastic containers ( 150 mEq/1,000mL ) . This factory-standardised, isotonic continuous-infusion presentation eliminates manual cleanroom compounding from hypertonic 8.4% vials under USP <797>, reducing the risk of bedside calculation errors and acute hypernatremia in intensive care units . ...
Read more

FDA June 2026 OPOE List: 699 Immediate ANDA Opportunities, Lupin’s Kalydeco Patent Win, & Global GMP Warnings

Image
Summary of this blog post: 5-minute read API & IP Intelligence Roundup (31 August 2026) This edition highlights major pipeline opportunities from the USFDA’s June 2026 Off-Patent, Off-Exclusivity (OPOE) list , key global regulatory compliance actions, and a major Hatch-Waxman patent ruling where Lupin defeated Vertex Pharmaceuticals over Kalydeco (ivacaftor) . 1. Niche Generic Pipeline: USFDA Releases Updated OPOE Drug List (June 2026) The USFDA published its biannual update to identify approved reference products that have no patent or regulatory exclusivity barriers and lack approved generic (ANDA) equivalents . Part I (Immediate Filing Opportunities): Lists 699 prescription products for which the Agency can immediately accept an ANDA without prior consultation . This includes 42 solid oral tablet products , such as: Oncology & Speciality: Chlorambucil (2 mg), Busulfan (2 mg), Mitotane (500 mg), and Hydroxyurea (100 mg) . Infectious Disease: Pivmecillinam HCl (Eq...
Location: Mumbai, Maharashtra, India
Read more

USFDA July 2026 ANDA Approvals: Indian Pharma Dominance, Antidiabetic Waves, US Tariffs, & EPO Patent Insights

Image
Two minutes read Summary: USFDA ANDAs & Global Pharma IP Roundup The US generic landscape in July 2026 saw rapid momentum across complex generics, notable patent expiries, and supply-chain realignments . This month’s intelligence roundup breaks down the 52 USFDA ANDA decisions , evaluates US generic drug tariff reshoring metrics , and examines an essential EPO Technical Board of Appeal patent revocation ruling . 1. July 2026 USFDA ANDA Approvals: Key Trends The USFDA granted 46 final approvals and 6 tentative approvals (TAs) across global manufacturers . Indian Generic Pharma Dominance: Indian drugmakers captured 46% of all regulatory decisions (20 final approvals, 4 TAs) . Aurobindo led with 3 approvals (Etodolac, Bupropion, Adapalene/Benzoyl Peroxide), followed by Macleods (Chlorthalidone, Dapsone), Zydus (Fluvoxamine, Edaravone), and Laurus Labs (Rilpivirine, TAF) . Antidiabetic Wave in Tentative Approvals: Five of the six tentative approvals focused on blockbuster an...
Location: Mumbai, Maharashtra, India
Read more